|
显示项目 740706-740715 / 2348419 (共234842页)
<< < 74066 74067 74068 74069 74070 74071 74072 74073 74074 74075 > >>
每页显示[10|25|50]项目
| 臺大學術典藏 |
2022-09-15T01:08:45Z |
Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
|
Hollebecque A.; Chung H.C.; Miguel M.J.D.; Italiano A.; MacHiels J.-P.; Chia-Chi Lin; Dhani N.C.; Peeters M.; Moreno V.; Su W.-C.; Chow K.H.; Galvao V.R.; Carlse M.; Yu D.; Szpurka A.M.; Zhao Y.; Schmidt S.L.; Gandhi L.; Xu X.; Bang Y.-J. |
| 國立成功大學 |
2021 |
Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
|
Hollebecque, A.;Chung, H.C.;Miguel, Miguel M.J.D.;Italiano, A.;MacHiels, J.-P.;Lin, C.-C.;Dhani, N.C.;Peeters, M.;Moreno, V.;Su, W.-C.;Chow, K.H.;Galvao, V.R.;Carlse, M.;Yu, D.;Szpurka, A.M.;Zhao, Y.;Schmidt, Schmidt S.L.;Gandhi, L.;Xu, Xu X.;Bang, Y.-J. |
| 臺大學術典藏 |
2022-08-19T00:20:40Z |
Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYnote-028 study
|
Hansen A.R.; Cheng J.D.; Thanigaimani P.; Saraf S.; CHIUN HSU; Lee S.-H.; Ejadi S.; Even C.; Cohen R.B.; Le Tourneau C.; Mehnert J.M.; Algazi A.; Van Brummelen E.M.J. |
| 臺大學術典藏 |
2020-04-10T12:51:01Z |
Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYNOTE-028 study
|
Chiun Hsu;Lee S.-H.;Ejadi S.;Even C.;Cohen R.B.;Le Tourneau C.;Mehnert J.M.;Algazi A.;Van Brummelen E.M.J.;Saraf S.;Thanigaimani P.;Cheng J.D.;Hansen A.R.; Chiun Hsu; Lee S.-H.; Ejadi S.; Even C.; Cohen R.B.; Le Tourneau C.; Mehnert J.M.; Algazi A.; Van Brummelen E.M.J.; Saraf S.; Thanigaimani P.; Cheng J.D.; Hansen A.R. |
| 臺大學術典藏 |
2020-05-25T07:35:07Z |
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer
|
Saraf S; Thanigaimani P; Cheng J.D; Keam B.; Mehnert J.M; Varga A; Brose M.S; Aggarwal R.R; Chia-Chi Lin; Prawira A; De Braud F; Tamura K; Doi T; Piha-Paul S.A; Gilbert J |
| 國立成功大學 |
2006-07 |
Safety and antiviral activity of pradefovir in patients with chronic hepatitis B virus infection: 48-week analysis of a phase 2 study
|
Lim, S. G.; Lee, K. S.; Chuang, W. L.; Hwang, S. G.; Cho, M.; Lai, M. Y.; Chao, Y. C.; Chang, Ting-Tsung; Han, K. H.; Lee, C. M.; Um, S. H.; Yeon, J. E.; Yang, S. S.; Teo, E. K.; Peng, C. Y.; Lin, H. H.; Yang, S. S.; Huo, T. I.; Nguyen, T.; Chen, T. Y.; Hu, K. Q.; Xu, Y.; Sullivan-Bolyai, J. Z. |
| 臺大學術典藏 |
2021-03-21T23:14:58Z |
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial
|
Patnaik, Amita; Yap, Timothy A.; Chung, Hyun Cheol; de Miguel, Maria J.; Bang, Yung Jue; Chia-Chi Lin; Su, Wu Chou; Italiano, Antoine; Chow, Kay Hoong; Szpurka, Anna M.; Yu, Danni; Zhao, Yumin; Carlsen, Michelle; Schmidt, Shelly; Vangerow, Burkhard; Gandhi, Leena; Xu, Xiaojian; Bendell, Johanna |
| 臺大學術典藏 |
2022-09-15T01:08:50Z |
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial
|
Patnaik A.; Yap T.A.; Chung H.C.; de Miguel M.J.; Bang Y.-J.; Chia-Chi Lin; Su W.-C.; Italiano A.; Chow K.H.; Szpurka A.M.; Yu D.; Zhao Y.; Carlsen M.; Schmidt S.; Vangerow B.; Gandhi L.; Xu X.; Bendell J. |
| 國立成功大學 |
2021 |
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial
|
Patnaik, A.;Yap, T.A.;Chung, H.C.;de, Miguel M.J.;Bang, Y.-J.;Lin, C.-C.;Su, W.-C.;Italiano, A.;Chow, K.H.;Szpurka, A.M.;Yu, D.;Zhao, Y.;Carlsen, M.;Schmidt, Schmidt S.;Vangerow, B.;Gandhi, L.;Xu, Xu X.;Bendell, J. |
| 臺大學術典藏 |
2018-09-10T09:52:57Z |
Safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept
|
Wang, T.-S. and Tsai, T.-F.; TSEN-FANG TSAI |
显示项目 740706-740715 / 2348419 (共234842页)
<< < 74066 74067 74068 74069 74070 74071 74072 74073 74074 74075 > >>
每页显示[10|25|50]项目
|
